RE:RE:RE:New and improvedI wouldn't say it has no value I would say that no one wants to pay for it right now. With the state of the company the vultures are circling and rightly or wrongly that's how the world works. You have valid points regarding Ipsen, Endo and to add to this there were
favourable comments made by the panel at ADCOM. There is value there but money has to be invested and trials performed to realize it and at the end of day there are no guarantees that it will be approved after that, it is logical to say the value is diluted given risk, time and expense. Given the what is known now through trials that have been performed and the highly regarded individuals supporting it, there is value, how much? I for one am glad that they have shelved it, it's not dead but if there is interest, they have to come and get it.
For those of you who want to oust the current management, have you really thought this through? Do your research and look at the state this company was in when they took it over. The decision was already made to go with one product only and many
If you do change management what are they going to do? Tell us the future looks bleak and we have no choice but to move the money elsewhere. This is after they have spent months researching the current state and after paying packages to current management, how much is left now?
I can see reducing the BOD head count and for sure removing James Rae.
I am certainly not happy with what's happened but it can't be changed, incurring more time and expense to oust the leadership does not make sense and be careful what you wish for, new management could be worse.